Gluetacs Therapeutic
Latest round
- Series A
Last raised
- May 2024
Total raised
- Undisclosed
Investors
- 8
About Gluetacs Therapeutic
Based in Shanghai, China and established in 2020, Gluetacs Therapeutic operates as a small-molecule innovative medicine company that focuses on proteolysis targeting chimeras and provides proteolysis targeting drugs (PROTAD). In November 2020, Gluetacs Therapeutic reached an exclusive license cooperation agreement for the research and development of small-molecule antitumor drugs worth more than RMB 1 billion. The co-founder as well as the CEO, Xiaobao Yang, worked at the Institute of Immunochemistry, University of Shanghai for Science and Technology. Gluetacs Therapeutic focuses on the development of novel oral small-molecule drugs by using protein degradation technology, and has established its own intellectual property rights for the development of molecular gel degraders (GLUE) and dual mechanism degraders (GLUETAC). The company has also established an artificial intelligence virtual screening platform, an in vitro pharmacodynamic screening platform, a pharmacokinetic platform, a proteomics platform and a tumor animal pharmacodynamic modeling platform. Its products are used in the fields of oncology and autoimmune diseases. Gluetacs Therapeutic generates revenue by licensing its proprietary drug candidates, providing drug development services, and collaborating with pharmaceutical companies on research and development projects.
Who invested in Gluetacs Therapeutic
8 investors across 2 rounds
See all investors in Gluetacs Therapeutic
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Gluetacs Therapeutic
Who invested in Gluetacs Therapeutic?
Gluetacs Therapeutic has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Gluetacs Therapeutic raised?
Gluetacs Therapeutic has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Gluetacs Therapeutic last raise money?
Gluetacs Therapeutic's most recent round on record is a Series A, in May 2024.
What does Gluetacs Therapeutic do?
Based in Shanghai, China and established in 2020, Gluetacs Therapeutic operates as a small-molecule innovative medicine company that focuses on proteolysis targeting chimeras and provides proteolysis targeting drugs (PROTAD).
Where is Gluetacs Therapeutic headquartered?
Gluetacs Therapeutic is headquartered in Shanghai, China.
Which VCs invest in companies like Gluetacs Therapeutic?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Gluetacs Therapeutic's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Gluetacs Therapeutic? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.